Table 1.
Overview of Nrf2-interacting factors in cancer cell lines
| Gene | Effects on Nrf2 | Effects on cell | Tumor model | Resistance to | References |
|---|---|---|---|---|---|
| P62 | Activator | Protective | SKOV3/DDP | Cisplatin | [48] |
| CD99 | Activator | Protective | A2780,COC1/DDP | Cisplatin | [50, 51] |
| ABCF2 | Activator | Protective | A2780 | Cisplatin | [52] |
| ATF2 | Inhibitor | Cytotoxic | SKOV3 | Cisplatin | [53] |
| AKR1C1 | Activator | Protective | – | Platinum | [54] |
| SIRT5 | Activator | Protective | A2780,SKOV3,CAOV3 | Cisplatin | [55] |
| SLC40A1 | Inhibitor | Cytotoxic | A2780CP,PEO4,COC1/DDP | Cisplatin | [56] |
| HER1 | Activator | Protective | PEO1, SKOV3, and OVCAR3 | lapatinib and erlotinib | [82] |
| HER2/HER3 | Activator | Protective | PEO4,OVCAR4,SKOV3 | Pertuzumab/Trastuzumab/Docetaxel | [80] |
| ABCG2 | Activator | Protective | SKOV3 | Mppa-PDT | [89] |
| GPX4 | Activator | Protective | AMC-HN2–11/SNU | Ferroptosis | [92, 93] |
| CBS | Activator | Protective | SKOV3 and OVCA429 | Ferroptosis | [94] |
| Compounds | |||||
| Brusatol | Inhibitor | Cytotoxic | SKOV3/HEC-1-A/A549 | – | [96] |
| Ailanthone | Inhibitor | Cytotoxic | A2780/CP70 | Cisplatin | [97] |
| Ascorbic acid | Inhibitor | Cytotoxic | KCL22/SR; Hela | Imatinib;cisplatin / adriamycin | [98, 99] |
| Apigenin | Inhibitor | Cytotoxic | BEL-7402/ADM | Doxorubicin | [100] |